For sponsors of mature defined-benefit schemes, the question of when to take the buy-in or buy-out conversation seriously has been answered. Multiple structural pressures — the TPR Funding Code’s bite on long-term funding objectives, the bulk-annuity market’s sustained capacity through 2024-26, the accounting and balance-sheet implications of carrying a mature DB obligation indefinitely — have moved the question from “if” to “when, on what terms, and in what shape”. The decision now turns on the specifics of price, residual position, and the analytical basis on which a sponsor is prepared to commit.
Why the decision is harder than the headline price
The headline price the bulk-annuity market quotes is one input. Whether to proceed is a different question, and a more substantive one. A defensible decision turns on three things the headline price doesn’t tell you: whether the price is consistent with an independent fair-value reading of the same liabilities, what residual position the transaction leaves on the sponsor’s balance sheet afterwards, and what the sponsor is prepared to accept or decline in advance of the quote-acceptance meeting.
Each of these is normally answered by a different adviser. The scheme actuary produces the funding-basis valuation. The transaction adviser handles negotiation with the BPA market. The sponsor’s covenant and finance teams track the post-transaction position. The sponsor carries the consequences of the transaction on its balance sheet and in its accounts — and is the party deciding, with its advisers, whether the offered terms are ones it can stand behind.
What an independent fair-value reading adds
An independent fair-value reading is a market-consistent valuation of the scheme’s pension liabilities — what the secured promise is worth to members, on a sound insured basis — produced by an actuary not party to the transaction. The output is not a predicted price and not a price range. It is a single reference value, and a reasoned reading of whether a given quote is consistent with that reference within a stated tolerance: a yes/no consistency conclusion, expressible where useful as a Gilts + x figure, with the reasoning set out. Where a quote sits within tolerance, the sponsor has an articulable basis for accepting it. Where it sits materially away from the reference, the sponsor has an articulable reason to investigate, to negotiate, or to decline — with the reading and its limits stated soberly.
The same reference value supports the sponsor in three downstream conversations. With the sponsor’s board: what residual risk does the transaction leave on the corporate balance sheet, and on what assumptions. With the auditor: what accounting position the transaction creates and whether the firm’s analysis can support the audit. With the scheme’s membership (via the trustees’ communication): why the transaction is fair to the secured benefit promise, in language a member can read.
Where Congruent is engaged
The firm is engaged where sponsors and their advisers want an independent reference value sitting alongside the transaction adviser’s work. The standard engagement is BPA Fair-Value Pricing — an independent check of whether the quoted premium is consistent with the risk-neutral fair value of the scheme’s promise to members, within a stated tolerance. It is a consistency assessment, not a price forecast and not a range. The firm does not model the insurer’s asset strategy, hedging or capital position; the insurer’s pricing economics are deliberately outside the scope of this engagement, and the firm is explicit about that boundary. The deliverable is the analytical position the sponsor can take into the transaction-decision meeting in its own words.
The Solution is a productised offering at the firm: the methodological framework and the productionised computation are established and operational. Engagement is scoped per transaction — sponsors and their advisers with substantive transactions in the pipeline are invited to engage the firm directly. The same senior actuary running the analysis is available for direct conversation with sponsors, sponsor advisers, transaction advisers, and auditors throughout.
The firm has no insurer commercial relationships, no broking pipeline, and no transaction-process fee structure — the firm’s independence on the question is structural rather than declarative. For matters extending beyond the BPA fair-value-consistency question into the wider retain-versus-transfer decision — setting the retain route (economic-capital) and the transfer route (regulatory-capital) on one comparable basis — further analytical work is available through the firm’s bespoke advisory engagement, Sponsor Fair-Value Analysis, under appropriate confidentiality.
Three questions before the next BPA conversation
The first question is whether the sponsor has an independent reading of the same liabilities the BPA market is pricing, on the same fair-value basis, against which to assess the quote. If the only valuation in the room is the funding-basis valuation produced for the triennial, the sponsor doesn’t have what it needs to evaluate the price.
The second is whether the residual position to the sponsor — what the sponsor’s balance sheet looks like after the transaction closes — is being thought about alongside the pricing reading. A transaction that improves the trustees’ position while creating an unmanageable residual position for the sponsor is a transaction that should not close on those terms. The sponsor and the trustees need a coordinated view of the post-transaction position, not two separate ones.
The third is whether the sponsor has, in advance, a defensible position on what it will accept and what it will decline. A sponsor that arrives at the quote-acceptance meeting without an independent reading and a worked-out residual position is one taking the transaction adviser’s word on the price. A sponsor that can defend the decision in its own words is in a different position altogether.
Last updated May 2026.